Experienced in Disseminated Intravascular Coagulation

Liang C. Dong

No.12 Urumqi Middle Road, 
Shanghai, CN 
Experienced in Disseminated Intravascular Coagulation
No.12 Urumqi Middle Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Liang Dong practices in Shanghai, China. Mr. Dong is rated as an Experienced expert by MediFind in the treatment of Disseminated Intravascular Coagulation. His top areas of expertise are Prostate Cancer, Asthma, Cerebral Hypoxia, Vertebroplasty, and Prostatectomy.

His clinical research consists of co-authoring 709 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Disseminated Intravascular Coagulation.

Gender
Male

Locations

No.12 Urumqi Middle Road, Shanghai, China
Other Locations
160 Pujian Road, Shanghai, 200127, China
16766 Jingshi Road, Jinan, 250014, China
No 555, YouYi East Road, Xi'an, China
1630 Dongfang Road, Dongfang, 200025, China
No. 48 Of East Wenhui Road, Yangzhou, 225009, China
No. 149 Dalian Road, Zunyi, 563000, China
71 Xinmin Street, Changchun, 130021, China
No. 28 Fuxing Road, Beijing, 100853, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug, Biological
Study Drug: GSK3511294
Study Phase: Phase 3
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Mepolizumab, Salbutamol
Study Phase: Phase 3
A Randomized, Single-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Relapsed/Refractory Ovarian Cancer
A Randomized, Single-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Relapsed/Refractory Ovarian Cancer
Enrollment Status: Completed
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: Manganese Chloride, Nab-paclitaxel, Platinum chemotherapy, Sintilimab
Study Phase: Phase 2
Anti-PD-1 Antibody SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase II Trial
Anti-PD-1 Antibody SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase II Trial
Enrollment Status: Unknown
Publish Date: April 01, 2019
Intervention Type: Drug
Study Drugs: SHR-1210 Anti-PD-1 Antibody, Decitabine
Study Phase: Phase 2
View 3 Less Clinical Trials

709 Total Publications

Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological and genetic mutation characteristics analysis of forty-two cases
Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological and genetic mutation characteristics analysis of forty-two cases
Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: September 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dong's expertise for a condition
ConditionClose
      View All 16 Advanced Conditions
      View All 113 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile